Comparison of Two Doses of Recombinant Human Chorionic Gonadotropin (rhCG) During Ovulation Induction in Intrauterine Insemination Cycles: A Prospective Randomized Clinical Trial

The purpose of this study was to compare the effectiveness of two doses of recombinant hCG (500 and 250 mu g) on the reproductive outcome through triggering of oocyte maturation. The study was a randomized controlled clinical trial. Healthy women undergoing IUI cycles (n = 66) were randomly assigned to one of two groups at the start of the cycle. Group control (n = 33) received rhCG (250 mu g) and group experiment (n = 33) received rhCG (500 mu g). Controlled ovarian hyperstimulation was achieved using clomiphene or letrozole and hMG. Semen specimens were washed using the swim up method and IUI using a volume of 0.3 mL was performed 42 h after rhCG injection. No difference was shown in terms of obtained total follicles and pregnancy rate in both groups. However, when all of the cycles who given 250 or 500 mu g of rhCG were stratified by the BMI (more and less than 25 kg m(-2)), Total follicles (more and less than 2 follicles) and infertility duration (more and less than 5 years), the reproductive outcome in the patients with less than 5 years infertility duration and less than 25 kg m(-2) BMI was more pronounced than the patients with more than 5 years infertility duration and more than 25 kg m(-2) BMI but the other parameter was not affected the reproductive outcome. No clinical or statistical improvement could be demonstrated, except infertility duration and BMI, for the higher dose of recombinant hCG in women. However, further well-designed studies are essential to offer a final conclusion.